Author:
Adachi Hisashi, ,Nakano Hitoshi,Yamamoto Kiichiro,Nakata Masashi,Bekki Hisatoshi,Honma Tomoki,Yoshiyama Hideki,Nohara Masatoshi
Publisher
Springer Science and Business Media LLC
Subject
Biochemistry, medical,Clinical Biochemistry,Endocrinology,Endocrinology, Diabetes and Metabolism
Reference33 articles.
1. Knopp RH, Dujovne CA, Le Beaut A, Lipka LJ, Suresh R, Veltri EP: Evaluation of efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract. 2003, 57: 363-8.
2. Denke M, Pearson T, Mcbride P, Gazzara RA, Brady WE, Tershakovec AM: Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diabetes Vasc Dis Res. 2006, 3: 93-102. 10.3132/dvdr.2006.020.
3. Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, Visseren FLJ: The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. Atherosclerosis. 2009, 202: 216-24. 10.1016/j.atherosclerosis.2008.04.035
4. Winkler K, Schewe T, Pütz G, Ödünc N, Schäfer G, Siegel E: Fluvastatin/fenofibrate vs. simvastatin/ ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles. Eur J Clin Invest. 2009, 39: 463-70. 10.1111/j.1365-2362.2009.02126.x
5. Robinson JG, Ballantyne CM, Grundy SM, Hsueh WA, Parving HH, Rosen JB: Lipid-altering efficacy and safety of ezetimibe/ simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET Study). Am J Cardiol. 2009, 103: 1694-702. 10.1016/j.amjcard.2009.05.003
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献